Evidence map›Paper›PMID 21593763›Full record

ArticleNature2011

Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.

Guillaume Lebon, Tony Warne, Patricia C Edwards, Kirstie Bennett, Christopher J Langmead, Andrew G W Leslie, Christopher G Tate

Open access · greenAbstract read
In one paragraph

Article in Nature, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 414 papers.

0numbers the graph read from it
0cells of the map it votes in
414citing papers in PubMed
38.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

414 citing papers in PubMed, 874 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Structural and Dynamics Insights into Melatonin Binding to MT1 Receptor.Chembiochem : a European journal of chemical biology · 2026
    Article
  7. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  8. Journal of the American Chemical Society · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Adenosine in the Brain: Recent Progress on Detection, Function, and Translation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Unlocking GPCR-ligand interactions: Measuring binding affinities with thermal shift assay.Protein science : a publication of the Protein Society · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article

354 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Guillaume LebonMRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK.
Tony Warne
Patricia C Edwards
Kirstie Bennett
Christopher J Langmead
Andrew G W Leslie
Christopher G Tate
MRC Laboratory of Molecular Biology · GBHeptares Therapeutics (United Kingdom) · GB

Funding

Biotechnology and Biological Sciences Research Council BB/G003653/1Medical Research Council MC_U105184325Medical Research Council MC_U105197215Medical Research Council U.1051.04.034
6 · The paper itself

Abstract

Adenosine receptors and β-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine or noradrenaline, respectively. GPCRs have similar structures consisting of seven transmembrane helices that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism. Recent structures of β-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors. Here we present two crystal structures of the thermostabilized human adenosine A(2A) receptor (A(2A)R-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA. The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site. The adenine substituent of the agonists binds in a similar fashion to the chemically related region of the inverse agonist ZM241385 (ref. 8). Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 277(7.42) and His 278(7.43); superscripts refer to Ballesteros-Weinstein numbering) and non-polar interactions with residues in H3. In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist. Comparison of the agonist-bound structures of A(2A)R with the agonist-bound structures of β-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helices 3, 5 and 7 may be a common feature in the activation of all GPCRs.

Indexed as

AdenosineAdenosine-5'-(N-ethylcarboxamide)Adenosine A2 Receptor AgonistsAnimalsBinding SitesCHO CellsCricetinaeCricetulusCrystallography, X-RayDrug Inverse AgonismHumansLigandsModels, MolecularMolecular ConformationReceptor, Adenosine A2ATriazinesAdenosineAdenosine-5'-(N-ethylcarboxamide)Adenosine A2 Receptor AgonistsLigandsReceptor, Adenosine A2ATriazinesTriazolesZM 241385

Identifiers

PMID21593763
PMCPMC3146096
OpenAlexW2102513649

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.